Meningococcal factor H binding proteins in epidemic strains from Africa: Implications for vaccine development

PLoS Neglected Tropical Diseases

Volumn 5, Issue 9, 2011, Pages

  Pajon, Rolando ^a   Fergus, Andrew M ^a   Koeberling, Oliver ^a,c   Caugant, Dominique A ^b   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; NATIVE OUTER MEMBRANE VESICLE VACCINE; POLYSACCHARIDE VACCINE; RECOMBINANT FACTOR H BINDING PROTEIN VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; FACTOR H BINDING PROTEIN, NEISSERIA MENINGITIDIS; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS;

AFRICA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GENOME; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG INHIBITION; EPIDEMIC; FEMALE; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MEMBRANE VESICLE; MENINGOCOCCOSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SEROPREVALENCE; TREATMENT RESPONSE; VACCINE PRODUCTION; ANIMAL; CLASSIFICATION; CROSS PROTECTION; CROSS REACTION; EPIDEMIC MENINGITIS; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; NEISSERIA MENINGITIDIS; SERUM BACTERICIDAL ACTIVITY;

AFRICA; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; CROSS PROTECTION; CROSS REACTIONS; DISEASE OUTBREAKS; FEMALE; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS;

EID: 80053451952     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001302     Document Type: Article

References (76)

1. Greenwood B, (1999) Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 93: 341-353.
2. Miller MA, Wenger J, Rosenstein N, Perkins B, (1999) Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr Infect Dis J 18: 1051-1059.
3. Wahdan MH, Sallam SA, Hassan MN, Abdel Gawad A, Rakha AS, et al. (1977) A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull World Health Organ 55: 645-651.
4. Wahdan MH, Rizk F, el-Akkad AM, el-Ghoroury AA, Hablas R, et al. (1973) A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull World Health Organ 48: 667-673.
5. Blakebrough IS, Greenwood BM, Whittle HC, Bradley AK, Gilles HM, (1983) Failure of meningococcal vaccination to stop the transmission of meningococci in Nigerian schoolboys. Ann Trop Med Parasitol 77: 175-178.
6. Moore PS, Harrison LH, Telzak EE, Ajello GW, Broome CV, (1988) Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA 260: 2686-2689.
7. Jodar L, Feavers IM, Salisbury D, Granoff DM, (2002) Development of vaccines against meningococcal disease. Lancet 359: 1499-1508.
8. Lee CH, Kuo WC, Beri S, Kapre S, Joshi JS, et al. (2009) Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 27: 726-732.
9. Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S, (2009) Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 27 (Suppl 2): B13-19.
10. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, et al. (2011) Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 364: 2293-2304.
11. Mueller JE, Borrow R, Gessner BD, (2006) Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines. Expert Rev Vaccines 5: 319-336.
12. Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, et al. (2007) Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 44: 657-663.
13. Forgor AA, Leimkugel J, Hodgson A, Bugri A, Dangy JP, et al. (2005) Emergence of W135 meningococcal meningitis in Ghana. Trop Med Int Health 10: 1229-1234.
14. Gagneux SP, Hodgson A, Smith TA, Wirth T, Ehrhard I, et al. (2002) Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 185: 618-626.
15. Castilla J, Vazquez JA, Salcedo C, Garcia Cenoz M, Garcia Irure JJ, et al. (2009) B:2a:p1.5 meningococcal strains likely arisen from capsular switching event still spreading in Spain. J Clin Microbiol 47: 463-465.
16. Trotter CL, Ramsay ME, Gray S, Fox A, Kaczmarski E, (2006) No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 6: 616-617.
17. Maiden MC, Stuart JM, (2002) Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359: 1829-1831.
18. Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, et al. (2005) Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116: e408-413.
19. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, et al. (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297: 1784-1792.
20. Alexandre C, Dubos F, Courouble C, Pruvost I, Varon E, et al. (2010) Rebound in the incidence of pneumococcal meningitis in northern France: effect of serotype replacement. Acta Paediatr 99: 1686-1690.
21. Hanage WP, Finkelstein JA, Huang SS, Pelton SI, Stevenson AE, et al. (2010) Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics 2: 80-84.
22. Hanquet G, Kissling E, Fenoll A, George R, Lepoutre A, et al. (2010) Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis 16: 1428-1439.
23. Granoff DM, (2010) Review of meningococcal group B vaccines. Clin Infect Dis 50 (Suppl 2): S54-65.
24. Khatami A, Pollard AJ, (2010) The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 9: 285-298.
25. Jacobsson S, Thulin S, Molling P, Unemo M, Comanducci M, et al. (2006) Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 24: 2161-2168.
26. Mothibeli KM, du Plessis M, von Gottberg A, Murphy E, Hoiseth SK, et al. (2011) Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine 29: 2187-2192.
27. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, et al. (2003) Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197: 789-799.
28. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, et al. (2004) Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72: 2088-2100.
29. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, et al. (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103: 10834-10839.
30. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, et al. (2010) Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28: 6086-6093.
31. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, et al. (2011) A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29: 1423-1420.
32. Zollinger WD, Donets MA, Schmiel DH, Pinto VB, Labrie J, et al. (2010) Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 28: 5057-5067.
33. Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, et al. (2011) Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 29: 4728-4734.
34. Koeberling O, Delany I, Granoff DM, (2011) A critical threshold of meningococcal factor h binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol 18: 736-742.
35. Koeberling O, Giuntini S, Seubert A, Granoff DM, (2009) Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 16: 156-162.
36. Hou VC, Koeberling O, Welsch JA, Granoff DM, (2005) Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 192: 580-590.
37. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, et al. (2006) The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177: 501-510.
38. Schneider MC, Exley RM, Chan H, Feavers I, Kang YH, et al. (2006) Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176: 7566-7575.
39. Granoff DM, Welsch JA, Ram S, (2009) Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77: 764-769.
40. Beernink PT, Granoff DM, (2008) Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 76: 2568-2575.
41. Plested JS, Welsch JA, Granoff DM, (2009) Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol 16: 785-791.
42. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, et al. (2010) Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 51: 1127-1137.
43. Snape MD, Dawson T, Oster P, Evans A, John TM, et al. (2010) Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 29: e71-79.
44. Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, et al. (2008) Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein. Infect Immun 76: 4232-4240.
45. Welsch JA, Ram S, Koeberling O, Granoff DM, (2008) Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 197: 1053-1061.
46. Goldschneider I, Gotschlich EC, Artenstein MS, (1969) Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 129: 1327-1348.
47. Borrow R, Carlone GM, Rosenstein N, Blake M, Feavers I, et al. (2006) Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24: 5093-5107.
48. Frasch CE, Borrow R, Donnelly J, (2009) Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27 (Suppl 2): B112-116.
49. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM, (2009) Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 199: 1360-1368.
50. Pajon R, Beernink PT, Harrison LH, Granoff DM, (2010) Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 28: 2122-2129.
51. Koeberling O, Seubert A, Granoff DM, (2008) Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 198: 262-270.
52. Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J, (2004) PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 10: 674-678.
53. Beernink PT, Granoff DM, (2009) The modular architecture of meningococcal factor H-binding protein. Microbiology 155: 2873-2883.
54. Koeberling O, Welsch JA, Granoff DM, (2007) Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Vaccine 25: 1912-1920.
55. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, et al. (2011) A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186: 3606-3614.
56. Welsch JA, Rossi R, Comanducci M, Granoff DM, (2004) Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 172: 5606-5615.
57. Granoff DM, Bartoloni A, Ricci S, Gallo E, Rosa D, et al. (1998) Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 160: 5028-5036.
58. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA, (2005) Molecular epidemiology of Neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 43: 5129-5135.
59. Norheim G, Rosenqvist E, Aseffa A, Yassin MA, Mengistu G, et al. (2006) Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989. J Clin Microbiol 44: 861-871.
60. Vu DM, Wong TT, Granoff DM, (2011) Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen. Vaccine 29: 1968-1973.
61. Leimkugel J, Hodgson A, Forgor AA, Pfluger V, Dangy JP, et al. (2007) Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana. PLoS Med 4: e101.
62. Caugant DA, Nicolas P, (2007) Molecular surveillance of meningococcal meningitis in Africa. Vaccine 25 (Suppl 1): A8-11.
63. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, et al. (2009) Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200: 379-389.
64. Seib KL, Brunelli B, Brogioni B, Palumbo E, Bambini S, et al. (2011) Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun 79: 970-981.
65. Chiavolini D, Weir S, Murphy JR, Wetzler LM, (2008) Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia. Clin Vaccine Immunol 15: 1322-1329.
66. Campbell H, Andrews N, Borrow R, Trotter C, Miller E, (2010) Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 17: 840-847.
67. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME, (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364: 365-367.
68. Borrow R, Andrews N, Findlow H, Waight P, Southern J, et al. (2010) Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 17: 154-159.
69. Perrett KP, Winter AP, Kibwana E, Jin C, John TM, et al. (2010) Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 50: 1601-1610.
70. Ram S, Lewis LA, Agarwal S, (2011) Meningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement. J Biol Chem 286: 8297-8307.
71. Poolman JT, De Vleeschauwer I, Durant N, Devos N, Feron C, et al. (2011) Measurement of functional anti-meningococcal serogroup A activity using strain 3125 as the target strain for serum bactericidal assay. Clin Vaccine Immunol 18: 1108-1117.
72. Ram S, Mackinnon FG, Gulati S, McQuillen DP, Vogel U, et al. (1999) The contrasting mechanisms of serum resistance of Neisseria gonorrhoeae and group B Neisseria meningitidis. Mol Immunol 36: 915-928.
73. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, et al. (2010) The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 6: e1001027.
74. Wang JF, Caugant DA, Li X, Hu X, Poolman JT, et al. (1992) Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun 60: 5267-5282.
75. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, et al. (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95: 3140-3145.
76. Dempsey JA, Wallace AB, Cannon JG, (1995) The physical map of the chromosome of a serogroup A strain of Neisseria meningitidis shows complex rearrangements relative to the chromosomes of the two mapped strains of the closely related species N. gonorrhoeae. J Bacteriol 177: 6390-6400.